What is ACRS's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.56B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ACRS?

P/E (TTM) is n/a and 52-week range is $2.10 to $6.60 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ACRS figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ACRS?

The company profile lists revenue (TTM) near $9M, net income (TTM) near -$7.83B, EPS (TTM) near -$0.59 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Aclaris Therapeutics, Inc. based, and what identifiers does Chartloom list?

The company context section lists headquarters in Wayne, Pennsylvania, US, 147.6M shares outstanding, ISIN US00461U1051 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Aclaris Therapeutics, Inc.

$ACRS

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. The company is headquartered in Wayne, Pennsylvania and currently employs 69 full-time employees. The company went IPO on 2015-10-07. The firm is engaged in developing novel small and large molecule product candidates for immuno-inflammatory diseases. Its proprietary KINect drug discovery platform coupled with its integrated discovery approach to small and large molecules enables the Company to identify and advance product candidates. The company provides contract research services to third parties enabled by its early-stage research and development expertise. The contract research segment is engaged in the provision of laboratory services. Its product candidate pipeline includes Bosakitug (ATI-045), ATI-2138 and ATI-052. The Bosakitug (ATI-045) is an investigational, novel, humanized anti-Thymic stromal lymphopoietin (TSLP) monoclonal antibody that specifically binds to human TSLP, blocking its interaction with the receptor complex and disrupting signal transduction. Its other investigational product candidate is Lepzacitinib (ATI-1777).

Employees

Website

www.aclaristx.com

IPO

2015-10-07

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US00461U1051

Headquarters

Wayne, Pennsylvania, US

Shares outstanding

147.6M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

77.85%

Browse other companiesFree AI scores and summaries for more stocks